A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE

Kidney International
L F QuintanaE Poch

Abstract

The arachidonic acid-derived metabolite 12-(S)hydroxyeicosatetraenoic acid (12(S)-HETE), catalyzed by 12-lipoxygenase (12-LOX, ALOX12), exhibits a variety of biological activities with implications in cardiovascular disease. Previous studies have shown higher urinary excretion of this metabolite in essential hypertension. The aim of this study was to analyze the association of polymorphisms in ALOX12 with hypertension and urinary levels of 12(S)-HETE. We studied 200 patients with essential hypertension (aged 56+/-1 years, mean+/-s.e.m., 97 males) and 166 matched controls (aged 54+/-1 years, 91 males). Out of six polymorphisms in the coding region of ALOX12, only R261Q determined a nonconservative amino-acid change and was evaluated by polymerase chain reaction and restriction digestion. Urinary 12(S)-HETE was measured in Sep-Pack-extracted samples using specific enzyme-linked immunosorbent assay. The distribution of genotypes of the R261Q polymorphism was significantly different between patients and controls: patients 92 (0.46) GG, 84 (0.42) GA, 24 (0.12) AA vs controls 56 (0.34) GG, 78 (0.47) GA, 32 (0.19) AA (P=0.030). On the contrary, no association was observed for two intronic polymorphisms. The urinary excretion of 12(S)-...Continue Reading

References

Nov 1, 1991·Hypertension·J C McGiffB Escalante
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·T IzumiB Samuelsson
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M L SchwartzmanR C Murphy
May 1, 1996·Hypertension·N SternE Knoll
May 1, 1996·The Journal of Clinical Endocrinology and Metabolism·I AntonipillaiR Horton
Jun 8, 1999·The Journal of Clinical Investigation·T CyrusC D Funk
Mar 7, 2001·Hypertension·D González-NúñezE Poch
Jan 18, 2003·Current Hypertension Reports·Esteban Poch
Dec 22, 2004·Kidney International·Daniel González-NúñezEsteban Poch

❮ Previous
Next ❯

Citations

Mar 29, 2011·Cancer Chemotherapy and Pharmacology·Austin M GuoAdnan R Munkarah
Aug 11, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·W-J XiaoZ-L Zhang
Sep 18, 2012·Journal of Lipid Research·Kenneth N IkeiMichael Holinstat
Feb 29, 2008·Journal of Lipid Research·Igor A Butovich, Svetlana M Lukyanova
Jul 27, 2011·Twin Research and Human Genetics : the Official Journal of the International Society for Twin Studies·Samantha J LuptonJoanne M Lind
May 3, 2014·Journal of Pharmaceutical and Biomedical Analysis·Isabella SquellerioViviana Cavalca
Aug 7, 2012·Familial Cancer·Vidudala V T S Prasad, Kolli Padma
Mar 16, 2007·Kidney International·C-M Hao, M D Breyer
Aug 25, 2015·Redox Biology·Ryuichi Mashima, Torayuki Okuyama
Oct 26, 2010·Progress in Lipid Research·Anca D DobrianJerry L Nadler
Feb 16, 2019·Epigenetics : Official Journal of the DNA Methylation Society·Jiaxuan LiuJennifer A Smith
Feb 7, 2019·The Pharmacogenomics Journal·Santiago CuevasPedro A Jose
Dec 3, 2017·International Urology and Nephrology·Athanasios K RoumeliotisPloumis S Passadakis
Mar 1, 2011·Experimental and Therapeutic Medicine·Vidudala V T S PrasadDivya Moganti
Jun 17, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhonghua ZhengShiwei Duan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.